May 25, 2022 | ~Home Feature| Press Release
Funding expected to provide sufficient capital for completion of Phase 3 trial for ex vivo product candidate for recessive dystrophic epidermolysis bullosa
Read MoreJanuary 10, 2022 | ~Home Feature| Press Release
Company adds in vivo capabilities to existing ex vivo approach for development of novel gene therapies
Read MoreOctober 21, 2021 | ~Home Feature| Press Release
RDEB is a devastating, rare genetic blistering disease with no FDA-approved treatments currently available
Read MoreOctober 14, 2021 | Media Coverage
FDA Awards 11 Grants to Clinical Trials to Develop New Medical Products for Rare Disease Treatments
Read MoreSeptember 29, 2021 | ~Home Feature| Press Release
Research to focus on osteogenesis imperfecta and classical Ehlers-Danlos syndrome, debilitating disorders with no FDA-approved treatments
Read MoreApril 20, 2021 | Press Release
Life sciences executive brings more than 25 years of experience to cell and gene therapy company progressing through pivotal Phase 3 clinical trial
Read MoreOctober 28, 2020 | Press Release
Company manufacturing and distributing D-Fi at in-house, cGMP commercial-scale facility in greater Philadelphia area
Read More